Nomic Bio announced a partnership with Broad Clinical Labs to integrate Nomic’s Nomic Omni 1000 immunoassay platform into BCL omics offerings. The collaboration is designed to embed multiplex proteomics into genomic disease-risk modeling and precision oncology workflows, including use in clinical trials and population-scale multiomics studies. Nomic’s Omni 1000 platform uses nELISA technology for multiplex immunoassays with absolute quantification and reports assays for more than 1,050 proteins. Nomic said early development work with BCL is underway and joint applications are expected to begin offering in early 2027. The deal also targets a long-standing challenge in translational proteomics: making proteomics datasets scalable, comparable, and usable alongside genomic modalities. BCL said the partnership is intended to improve biomarker development and clinical applications by tightening the link between assay output and downstream decision-making.